spacer
home > pmps > winter 2017 > play it cool
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Play it Cool

As pharmaceutical and biological logistics spending booms towards an estimated $86 billion dollar industry by 2018, regulatory agencies have begun to place more scrutiny on the adherence of temperature requirements during transportation. The sector is racing to catch up to meet the needs of proper temperature management for a wider range of products, including refrigerated, frozen and control room temperatures that are being delivered through evolving methods such as mail orders. As new technologies and practices evolve to provide for the growing demand, it is important to understand their fundamentals in order to avoid misconceptions and be able to detect false claims.

During Shipping

With the availability of smaller, cheaper and less sophisticated temperature monitoring devices, it can be tempting to use them on a regular basis to determine conditions during transportation. However, with the wide variety for sale and the numerous variables that can impact the quality of their readings, these can be misleading. Most only measure the air temperature, which can vary by several degrees from the pharmaceutical or biologic’s actual temperature – especially if the product is liquid.

Some low cost indicators utilise chemical conversions to give a general idea if the desired conditions have been maintained. These devices have a broad accuracy relative to a tight range, typically of 2-8°C. Another downfall is that most require a set storage time within a specific temperature range before they can be used. Once they are ready, they must be maintained within the temperature range, otherwise false readings can occur. This is possible during packing or when the containers are opened at their destination, which could trigger an excursion reading when the drug is not even in contact with the indicator.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jean-Pierre Emond, Chief Operating Officer of The Illuminate Group, received his PhD in 1992 from the University of Florida, US, where he is now a courtesy professor. Jean-Pierre was previously the Director of Cold Chain Research at the Georgia Tech Research Institute and has over 300 technical communications and 25 patents in packaging, transport and distribution.

Melissa Germain is the Chief Executive Officer of The Illuminate Group. Since 2008, she has served as the Director of the Academic Cold Chain Forum, where key players in the food and pharma sectors meet to discuss and solve issues in the cold chain industry and broaden their knowledge of temperature management. She graduated from the University of Florida, US, with a BSc in 2009 and an MSc in Agricultural and Biological Engineering in 2010.
spacer
Dr Jean-Pierre Emond
spacer
spacer
spacer
Melissa Germain
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kindeva Drug Delivery, Formerly 3M Drug Delivery Systems, Launches as an Independent Company

Kindeva is a leading global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with a wealth of expertise in formulation, product development and manufacturing. Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company's microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement